Jay Peredo

Day 3 Update on Tirz + BPC-157 > Nausea has subsided > Woke up again after 6 hours of sleep > Ate ~1200 calories, mostly protein slop. Hard to eat more > Scared I'm going to lose all my muscle mass > Getting Dexa scan today to make sure Any tips on improving sleep?

Peptide Sciences, arguably one of the largest research peptide vendors, just announced they’re shutting down. That’s a pretty big deal considering how long they’ve been around. It also likely won’t be the last. As compounding pharmacies gain clearer pathways to prescribe peptides, the old “research peptide” vendor model becomes harder to sustain. A few things worth knowing: - This doesn’t mean peptides are going away - Some gray-market vendors will likely disappear - New ones will also show up quickly When a big vendor disappears, the market doesn’t disappear. It fragments.

Expect a massive surge in compounding pharmacies, explicit warning labels on gray market peptides (currently is “not for human use”… ) and steep penalties for any venue besides Lilly selling Retatrutide. And per prediction, NIH budget to be increased 1%. More on that soon…

Expect a massive surge in compounding pharmacies, explicit warning labels on gray market peptides (currently is “not for human use”… ) and steep penalties for any venue besides Lilly selling Retatrutide. And per prediction, NIH budget to be increased 1%. More on that soon…

RFK Jr. was just on Joe Rogan’s podcast and said ~14 peptides currently restricted under the FDA’s Category 2 list could soon be eligible for legal compounding again. If implemented, that would materially EXPAND peptide access in the U.S. Category 2 status currently restricts compounding due to safety concerns. Moving substances to Category 1 would allow regulated U.S. pharmacies to compound them under oversight, potentially reducing reliance on unregulated sourcing. Access expansion changes behavior quickly. If more peptides become legally compoundable, we’ll likely see: - More first-time users - More stacking - Faster experimentation - More telehealth activity But increased availability doesn’t automatically improve outcomes. More compounds in circulation often means: - Overlapping protocols - Escalation mistakes - Inconsistent cycles - Less clarity on what’s actually working Regulatory shifts may improve supply chain oversight. They don’t replace execution discipline. Whether 14 peptides move or not, one variable remains constant: Outcomes depend on structured use. Clear protocols. Intentional dosing. Consistent tracking. If peptide access expands, structured protocol management becomes even more important. That’s exactly why PepTracker exists.

🚨 BREAKING NEWS: RFK Jr. says ~14 of 19 banned peptides can be legally compounded again by US pharmacies within a few weeks. This will ensure Americans are getting "a good product… from ethical suppliers" vs. black market drug dealers that provide "substandard product" with serious safety risks. The 19 compounds on FDA’s Category 2 compounding safety list include: • BPC-157 • Cathelicidin LL-37 • Emideltide (DSIP) • Epitalon • GHK-Cu (injectable) • GHRP-2 (injectable/nasal) • GHRP-6 • Ipamorelin acetate • Kisspeptin-10 • KPV • Melanotan II • PEG-MGF (pegylated Mechano Growth Factor) • MOTS-C • Semax • Thymosin beta-4 fragment (LKKTETQ) • AOD-9604 • CJC-1295 • Selank acetate (TP-7) • Thymosin-alpha 1 (Ta1) The five least likely to be legalized in a policy shift would be those with the most troubling safety signals or the weakest human data — for example: Melanotan II, Cathelicidin LL-37, GHRP-2, Ipamorelin acetate, and CJC-1295 — because of documented serious adverse events or other red flags in FDA’s risk assessment.